奥尔芬和间苯三酚联合用药与单一用药治疗急性肾绞痛的临床疗效比较

目的 比较奥尔芬和间苯三酚联合用药与单一用药治疗急性肾绞痛的临床疗效。方法 将255 例 急性肾绞痛患者按随机数字表法分为奥尔芬联合间苯三酚治疗组（联合治疗组）、奥尔芬对照组和间苯三酚 对照组，每组85 例。联合治疗组给予肌内注射奥尔芬95 mg，静脉滴注间苯三酚80 mg ；奥尔芬对照组给予 肌内注射奥尔芬95 mg ；间苯三酚对照组给予静脉滴注间苯三酚80 mg。分别于给药后10、20 和40 min 观察 镇痛效果及其不良反应。结果 治疗40 min 后，联合治疗组的VAS 评分为（3.3±2.4）分，低于奥尔芬对照组 （4.5±3.0）分和间苯三酚对照组（4.6±3.4）分；总有效率为95.3%（81/85），高于奥尔芬对照组85.9% 和间 苯三酚对照组83.5% ；持续有效率为88.9%（72/81），高于奥尔芬对照组61.6% 和间苯三酚对照组35.4% ；起 效时间为（13.0±5.2）min，短于奥尔芬对照组（18.0±6.0）min 和间苯三酚对照组（19.0±7.5）min ；疼痛 缓解持续时间为（4.6±1.5）h，长于奥尔芬对照组（2.8±1.6）h 和间苯三酚对照组（2.6±1.8）h。不良反应 发生率为7.1%（6/85），与奥尔芬对照组和间苯三酚对照组相近。结论 奥尔芬联合间苯三酚治疗泌尿系结石 导致的急性肾绞痛，安全有效，值得在临床推广使用。

Comparison of clinical efficacy of combined use of Olfen and Phenylene trihydroxybenzene with single drug use in treatment of acute renal colic

Objective To compare clinical efficacy and safety of combined use of Olfen and Phenylene trihydroxybenzene with single use of the drugs in the treatment of acute renal colic. Methods Two hundreds and fifty-five patients with acute renal colic were randomly divided into three groups with 85 in each group. The combined treatment group was administrated with intramuscular injection of 95 mg Olfen and intravenous drop infusion of 80 mg Phenylene trihydroxybenzene. The Olfen control group was administrated with intramuscular injection of 95 mg Olfen and the Phenylene trihydroxybenzene control group was given intravenous drop infusion of 80 mg Phenylene trihydroxybenzene. The efficacy and the side effects were observed 10, 20, and 40 min after administration and compared between the three groups. Results At 40 min after administration, the total efficacy rate and sustained efficacy rate of the combined treatment group (95.3% and 88.9%) were higher than those of the Olfen control group (85.9% and 61.6%) and the Phenylene trihydroxybenzene control group (83.5% and 35.4%). The onset time of drug in the combined treatment group was shorter than that in the Olfen control group and the Phenylene trihydroxybenzene control group (13.0 ± 5.2) min vs. (18.0 ± 6.0) min and (19.0 ± 7.5) min]. The pain remission duration in the combined treatment group was longer than that in the Olfen control group and the Phenylene trihydroxybenzene control group (4.6 ± 1.5) h vs. (2.8 ± 1.6) h and (2.6 ± 1.8) h]. The adverse reaction rate in the combined treatment group was 7.1% (6/85), which was similar with that in the Olfen control group and the Phenylene trihydroxybenzene control group. Conclusions Olfen combined with Phenylene trihydroxybenzene is a safe and effective therapy for patients with acute renal colic, and is worthy of clinical application.